LEO Pharma: Dermatitis trials

The registry lists 34 Dermatitis studies with LEO Pharma as lead sponsor. 0 are open to participants now and 13 have results posted.

Phase 1 13Phase 2 8Phase 3 8Phase 4 2No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe ADCompletedNCT05470114Phase 2Results posted
• Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)CompletedNCT05194540Phase 3Results posted
• An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.CompletedNCT04922021Phase 2Results posted
• Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic DermatitisCompletedNCT04587453Phase 3Results posted
• Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7CompletedNCT03761537Phase 3Results posted
• Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.CompletedNCT03725722Phase 2Results posted
• Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTENDCompletedNCT03587805Phase 3Results posted
• Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)CompletedNCT03562377Phase 2Results posted
• Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).CompletedNCT03526861Phase 3Results posted
• Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3CompletedNCT03363854Phase 3Results posted
• Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)CompletedNCT03160885Phase 3Results posted
• Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)CompletedNCT03131648Phase 3Results posted
• LEO 29102 Cream in the Treatment of Atopic DermatitisCompletedNCT01037881Phase 2Results posted
• A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese SubjectsCompletedNCT05099133Phase 1
• Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and ChildrenCompletedNCT03826901Phase 1
• Investigation of Flare and Remission in Subjects With Atopic DermatitisWithdrawnNCT03710044Phase 4
• Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4CompletedNCT03556592Phase 1
• Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic DermatitisCompletedNCT03514511Phase 1
• Skin IaM: An Exploratory Clinical Trial to Evaluate Changes in Skin Appearance, Colour, and/or Texture Following the Induction of a Local Inflammatory Skin ResponseCompletedNCT03192280Not applicable
• An Observational Study Investigating the Treatment Satisfaction of Atopic Dermatitis Patients Who Have Switched to Ointment (W/O Emulsion) Formulation of Very Strong Class Topical CorticosteroidsCompletedNCT02627989
• An Explorative Trial Evaluating the Effect of LEO 32731 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)CompletedNCT02496546Phase 1
• A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)CompletedNCT02376049Phase 1
• Effect of LEO 39652 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)CompletedNCT02219633Phase 1
• A Multi-Centre Clinical Trial to Evaluate a Left-Right Design in Adults With Mild to Moderate Atopic DermatitisCompletedNCT02103725Phase 1
• Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 CreamCompletedNCT01850849Phase 1
• Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis.TerminatedNCT01447758Phase 1
• Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects by Dermal Application of a LEO 29102CompletedNCT01423656Phase 1
• A Safety, Tolerability and Pharmacokinetic Study of LEO 29102 in Subjects With Atopic DermatitisCompletedNCT01005823Phase 1
• Assessment of the Phototoxic Potential of LEO 29102 CreamCompletedNCT00958516Phase 1
• A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic DermatitisTerminatedNCT00475605
• A Study of Azelaic Acid (AzA) 15% Gel in the Treatment of Seborrheic Dermatitis of the FaceCompletedNCT00408330Phase 2
• A Study of Azelaic Acid (AzA) 15% in Topical Treatment of Mild to Moderate Perioral DermatitisCompletedNCT00403949Phase 2
• LEO19123 Cream in the Treatment of Atopic DermatitisCompletedNCT00392067Phase 2
• Efficacy and Safety Study of Advantan for Maintenance Treatment of Atopic DermatitisCompletedNCT00185510Phase 4